Labo Euromedis (XPAR:ALEMG) Beta: 0.2930 (As of Jul. 13, 2026)


XPAR:ALEMG Labo Euromedis XPAR:ALEMG
61 GF Score
Price €4.88
GF Value €4.48
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Labo Euromedis Beta?

Labo Euromedis XPAR:ALEMG 61 Beta is 0.2930 as of Jul. 13, 2026. GuruFocus rates XPAR:ALEMG with a GF Score™ of 61/100 and a GF Value™ of €4.48 (Fairly Valued). The stock has 6 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-13), Labo Euromedis's Beta is 0.2930.


Labo Euromedis  (XPAR:ALEMG) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Labo Euromedis Beta Related Terms


Labo Euromedis Beta Historical Data

* Premium members only.

The historical data trend for Labo Euromedis's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labo Euromedis Beta Chart

Labo Euromedis Annual Data
Trend Jul15 Jul16 Jul17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.55 -1.00 -0.12 0.02 0.13

Labo Euromedis Semi-Annual Data
Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.19 0.02 -0.24 0.13

XPAR:ALEMG vs MCK, CAH, COR: Beta Comparison

For the Medical Distribution subindustry, Labo Euromedis's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Labo Euromedis Beta vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Labo Euromedis's Beta distribution charts can be found below:

* The bar in red indicates where Labo Euromedis's Beta falls into.


XPAR:ALEMG
61GF Score
Labo Euromedis XPAR:ALEMG
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Labo Euromedis Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.2930 mean?
Labo Euromedis (XPAR:ALEMG) has a Beta of 0.2930 as of Jul. 13, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Labo Euromedis and its competitors.
Is Labo Euromedis' Beta too high?
Labo Euromedis' current Beta is 0.2930. Overall, Labo Euromedis has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' Beta compare to MCK and CAH?
Labo Euromedis' Beta of 0.2930 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Distribution company?
A good Beta depends on the Medical Distribution industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Labo Euromedis and its competitors. Labo Euromedis's current Beta is 0.2930. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Based on GuruFocus' analysis, Labo Euromedis (XPAR:ALEMG) is currently considered Fairly Valued. The stock's GF Value™ is €4.48, compared to a current price of €4.88 — trading 8.9% above its estimated fair value. The current Beta is 0.2930. Labo Euromedis' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Labo Euromedis (XPAR:ALEMG), the current Beta is 0.2930 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Labo Euromedis (XPAR:ALEMG) Overvalued in 2026?

Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued. The current stock price of €4.88 is trading 8.9% above its estimated GF Value™ of €4.48. GuruFocus considers Labo Euromedis to be Fairly Valued.

Key valuation signals for XPAR:ALEMG:

  • Beta: 0.2930
  • GF Value™: €4.48 vs. price of €4.88 (8.9% above fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the XPAR:ALEMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Labo Euromedis Business Description

Other Exchanges 0I0L:UK61R:Germany
Address ZI de la Tuilerie, Neuilly-sous-Clermont, FRA, 60290
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
61GF Score

Get the complete analysis for XPAR:ALEMG

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.88
Price
€4.48
GF Value